Citadel Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.4M | Buy |
581,093
+272,622
| +88% | +$6.49M | ﹤0.01% | 2736 |
|
|
2025
Q4 | $7.2M | Sell |
308,471
-89,425
| -22% | -$1.99M | ﹤0.01% | 3715 |
|
|
2025
Q3 | $7.84M | Buy |
397,896
+137,904
| +53% | +$2.84M | ﹤0.01% | 3610 |
|
|
2025
Q2 | $5.64M | Sell |
259,992
-425,424
| -62% | -$10M | ﹤0.01% | 3902 |
|
|
2025
Q1 | $16.6M | Buy |
685,416
+248,949
| +57% | +$5.61M | ﹤0.01% | 2241 |
|
|
2024
Q4 | $9.11M | Buy |
436,467
+411,229
| +1,629% | +$8.83M | ﹤0.01% | 3108 |
|
|
2024
Q3 | $502K | Sell |
25,238
-557,683
| -96% | -$10.3M | ﹤0.01% | 8253 |
|
|
2024
Q2 | $9.03M | Sell |
582,921
-535,519
| -48% | -$8.34M | ﹤0.01% | 2900 |
|
|
2024
Q1 | $17.8M | Buy |
1,118,440
+608,336
| +119% | +$9.17M | ﹤0.01% | 2196 |
|
|
2023
Q4 | $8.57M | Buy |
510,104
+29,281
| +6% | +$400K | ﹤0.01% | 3053 |
|
|
2023
Q3 | $5.62M | Buy |
480,823
+315,729
| +191% | +$4.22M | ﹤0.01% | 3473 |
|
|
2023
Q2 | $2.22M | Sell |
165,094
-264,519
| -62% | -$3.81M | ﹤0.01% | 4978 |
|
|
2023
Q1 | $7.12M | Buy |
429,613
+383,866
| +839% | +$6.33M | ﹤0.01% | 3260 |
|
|
2022
Q4 | $851K | Buy |
+45,747
| New | +$704K | ﹤0.01% | 7129 |
|
|
2022
Q3 | – | Sell |
-193,949
| Closed | -$2.3M | – | 12741 |
|
|
2022
Q2 | $1.36M | Sell |
193,949
-19,463
| -9% | -$143K | ﹤0.01% | 6342 |
|
|
2022
Q1 | $1.77M | Buy |
213,412
+25,229
| +13% | +$178K | ﹤0.01% | 6366 |
|
|
2021
Q4 | $1.27M | Sell |
188,183
-72,376
| -28% | -$476K | ﹤0.01% | 7307 |
|
|
2021
Q3 | $1.38M | Buy |
260,559
+53,516
| +26% | +$293K | ﹤0.01% | 7316 |
|
|
2021
Q2 | $1.19M | Buy |
207,043
+163,506
| +376% | +$844K | ﹤0.01% | 7889 |
|
|
2021
Q1 | $201K | Sell |
43,537
-139,000
| -76% | -$552K | ﹤0.01% | 11689 |
|
|
2020
Q4 | $610K | Sell |
182,537
-27,652
| -13% | -$92.9K | ﹤0.01% | 7781 |
|
|
2020
Q3 | $625K | Buy |
+210,189
| New | +$822K | ﹤0.01% | 6882 |
|
|
2020
Q2 | – | Sell |
-874,712
| Closed | -$3.93M | – | 9854 |
|
|
2020
Q1 | $3.37M | Sell |
874,712
-317,449
| -27% | -$1.3M | ﹤0.01% | 3283 |
|
|
2019
Q4 | $4.47M | Buy |
1,192,161
+1,129,323
| +1,797% | +$5.28M | ﹤0.01% | 3221 |
|
|
2019
Q3 | $334K | Sell |
62,838
-41,340
| -40% | -$220K | ﹤0.01% | 7407 |
|
|
2019
Q2 | $400K | Buy |
104,178
+88,859
| +580% | +$384K | ﹤0.01% | 7148 |
|
|
2019
Q1 | $78K | Sell |
15,319
-55,875
| -78% | -$164K | ﹤0.01% | 8644 |
|
|
2018
Q4 | $137K | Buy |
71,194
+53,926
| +312% | +$154K | ﹤0.01% | 8104 |
|
|
2018
Q3 | $65K | Buy |
17,268
+3,217
| +23% | +$10.1K | ﹤0.01% | 8737 |
|
|
2018
Q2 | $44K | Sell |
14,051
-87,402
| -86% | -$265K | ﹤0.01% | 8464 |
|
|
2018
Q1 | $242K | Sell |
101,453
-52,381
| -34% | -$174K | ﹤0.01% | 7053 |
|
|
2017
Q4 | $602K | Buy |
153,834
+143,697
| +1,418% | +$475K | ﹤0.01% | 5378 |
|
|
2017
Q3 | $26K | Sell |
10,137
-650
| -6% | -$1.78K | ﹤0.01% | 7316 |
|
|
2017
Q2 | $30K | Buy |
+10,787
| New | +$22.5K | ﹤0.01% | 7202 |
|
|
2016
Q2 | – | Sell |
-63,270
| Closed | -$74K | – | 6877 |
|
|
2016
Q1 | $74K | Sell |
63,270
-115,364
| -65% | -$179K | ﹤0.01% | 6146 |
|
|
2015
Q4 | $437K | Buy |
178,634
+36,411
| +26% | +$104K | ﹤0.01% | 4648 |
|
|
2015
Q3 | $426K | Buy |
142,223
+62,462
| +78% | +$270K | ﹤0.01% | 5025 |
|
|
2015
Q2 | $329K | Buy |
79,761
+44,463
| +126% | +$177K | ﹤0.01% | 5618 |
|
|
2015
Q1 | $153K | Sell |
35,298
-2,999
| -8% | -$10.8K | ﹤0.01% | 6460 |
|
|
2014
Q4 | $113K | Sell |
38,297
-44,622
| -54% | -$122K | ﹤0.01% | 6541 |
|
|
2014
Q3 | $275K | Buy |
82,919
+61,341
| +284% | +$160K | ﹤0.01% | 5367 |
|
|
2014
Q2 | $55K | Buy |
21,578
+13,979
| +184% | +$29.9K | ﹤0.01% | 6688 |
|
|
2014
Q1 | $17K | Sell |
7,599
-11,871
| -61% | -$24.8K | ﹤0.01% | 7354 |
|
|
2013
Q4 | $38K | Buy |
+19,470
| New | +$39.4K | ﹤0.01% | 6179 |
|
|
2013
Q3 | – | Sell |
-16,861
| Closed | -$15K | – | 6745 |
|
|
2013
Q2 | $15K | Buy |
+16,861
| New | +$13.5K | ﹤0.01% | 6135 |
|
Other funds holding CPRX
VCM
DM
VPM
Citadel Advisors's CPRX Position: Q1 2026 in Review
Citadel Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 88% in Q1 2026, buying an estimated $6.49M and bringing the position to 581,093 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.
Citadel Advisors first reported a position in CPRX in Q2 2013 and has held it in 45 quarters since. The position peaked at $17.8M in Q1 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Citadel Advisors held 581,093 shares of Catalyst Pharmaceutical worth $14.4M as of Q1 2026.
- Citadel Advisors bought 272,622 Catalyst Pharmaceutical shares in Q1 2026, an estimated $6.49M.
- Catalyst Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2736 holding.
- Citadel Advisors first reported a position in Catalyst Pharmaceutical in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's Catalyst Pharmaceutical position peaked at $17.8M in Q1 2024.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.